Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced today the appointment of Errol De Souza, Ph.D., to its board of directors.
Dr. De Souza is a seasoned R&D and business leader with broad experience - from large pharma to start ups - in the discovery and development of therapeutics for the treatment of central nervous system (CNS) disorders. Dr. De Souza is currently the executive chairman of Bionomics Limited and a member of the board of directors of Royalty Pharma and Catalyst Biosciences. Previously, Dr. De Souza founded Neurocrine Biosciences, Inc., served as CEO of numerous publicly traded and private companies, including Biodel, Inc., Synaptic Pharmaceutical Corp., Archemix Corp. and Neuropore Therapies, Inc. In addition, he led CNS R&D at DuPont Merck and US R&D at Aventis. Dr. De Souza received a B.A. in physiology and a Ph.D. in endocrinology from the University of Toronto.
"We are excited to welcome Errol to the Cyclerion Board of Directors. With deep expertise in CNS drug development and strategic business experience at the highest levels of biotech leadership, Errol will provide important counsel to help shape the future of Cyclerion," said Peter Hecht, Ph.D. chief executive officer of Cyclerion. “We seek board members with strong strategic judgment, an owner-oriented mindset, business savvy, a strong interest in our company, and absolute integrity, and Errol embodies all of those attributes and will serve as an outstanding representative of our shareholders and advisor to our company.”
"I have great respect for the Cyclerion team's drug-making expertise and the potential for modulation of the NO-sGC-cGMP pathway to positively impact brain physiology," said Dr. De Souza. "I look forward to joining Cyclerion's highly-committed board at this pivotal time to provide guidance on the company's strategy and support the mission of crating therapies that restore cognitive function for patients."
About Cyclerion Therapeutics
Forward Looking Statement